IDO1 and glioblastoma: Their lead compound, NU223612 (Table 2), demonstrated breakthrough efficacy in orthotopic glioblastoma models, achieving robust IDO1 degradation within the intracranial tumor niche - a feat particularly notable given the historically poor penetration of most therapeutic agents into the central nervous system.